

IN THE CLAIMS:

1-36. (canceled)

37. (previously presented) An antibody composition that specifically binds to an epitope of a hydrophobic cell wall protein of a yeast from the *Candida* genus and inhibits the binding of the yeast to a tissue of a mammalian host.

38. (previously presented) The antibody composition of claim 37 wherein the antibody is selected from the group consisting of 1C1 antibody, humanized 1C1 antibody, and fragments and mixtures thereof.

39. (previously presented) The antibody composition of claim 37, wherein the hydrophobic cell wall protein mediates adhesion of the yeast to the tissue under conditions of physiological shear present in the tissue.

40. (previously presented) The antibody composition of claim 37, wherein the antibody is selected from the group consisting of IgG, IgA and IgM.

41. (previously presented) The antibody composition of claim 37, wherein the yeast is selected from the group consisting of *C. albicans*, *C. kefyr*, *C. lipolytica*, *C. rugosa*, *C. stellatoidea* and *C. tropicalis* and strains thereof.

42. (previously presented) The antibody composition of claim 37, wherein the molecular weight of the hydrophobic cell wall protein, as determined by SDS-PAGE, is less than about 90 kDa.

43. (previously presented) The antibody composition of claim 42, wherein the molecular weight of the hydrophobic cell wall protein is between about 20-70 kDa.

44. (previously presented) The antibody composition of claim 43, wherein the molecular weight of the hydrophobic cell wall protein is about 37 kDa, about 38 kDa, about 40 kDa or about 41 kDa.

45. (previously presented) The antibody composition of claim 43, wherein the yeast is *Candida tropicalis*.

46. (previously presented) The antibody composition of claim 45, wherein the molecular weight of the hydrophobic cell wall protein is about 40 kDa or about 54 kDa.

47. (previously presented) The antibody composition of claim 43, wherein the yeast is *Candida kefyr*.

48. (previously presented) The antibody composition of claim 47, wherein the molecular weight of the hydrophobic cell wall protein is about 36 kDa, 55 kDa or about 59 kDa.

49. (previously presented) The monoclonal antibody 1C1.

50. (previously presented) A hybridoma that expresses the 1C1 antibody of claim 49.

51. (previously presented) A pharmaceutical composition comprising the antibody composition of claim 37.

52. (previously presented) The pharmaceutical composition of claim 51, further comprising a pharmaceutically acceptable carrier or excipient.

53. (previously presented) The pharmaceutical composition of claim 51, further comprising a pharmaceutically acceptable carrier and excipient.

54. (previously presented) The pharmaceutical composition of claim 52 or 53, formulated for systemic administration.

55. (previously presented) The pharmaceutical composition of claim 52 or 53, formulated for topical administration.

56. (previously presented) The pharmaceutical composition of claim 52 or 53, formulated as an aerosol.

57. (previously presented) The pharmaceutical composition of claim 52 or 53, further comprising one or more additional therapeutic agents.

58. (previously presented) The pharmaceutical composition of claim 57, wherein said one or more additional therapeutic agents is an anti-fungal agent.

59. (previously presented) The pharmaceutical composition of claim 58, wherein the antifungal agent is selected from the group consisting of flucytosine, mycoconazole, fluconazole, itraconazole, ketoconazole, griseofulvin, amphotericin B, sulfadiazine, penicillin, chlortetracycline, chloramphenicol, streptomycin, and mixtures thereof.

60. (previously presented) The pharmaceutical composition of claim 51, 52 or 53, wherein the antibody is selected from the group consisting of 1C1 antibody, humanized 1C1 antibody, and fragments and mixtures thereof.

61. (previously presented) A method of treating candidiasis in a subject comprising the step of administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 51.

62. (previously presented) The method of claim 61, wherein the candidiasis is disseminated candidiasis or mucocutaneous candidiasis.

63. (previously presented) The method of claim 61, wherein the antibody is selected from the group consisting of 1C1 antibody, humanized 1C1 antibody, and fragments and mixtures thereof.

64. (previously presented) A test kit for detecting a hydrophobic cell wall protein of a yeast from the *Candida* genus comprising the antibody composition of claim 37 and a reagent for detecting binding of the antibody to the hydrophobic cell wall protein.

65. (previously presented) The test kit of claim 64, wherein the antibody is selected from the group consisting of 1C1 antibody, humanized 1C1 antibody, and fragments and mixtures thereof.

66. (currently amended) A substantially pure hydrophobic cell wall protein of a yeast of the *Candida* genus that mediates adhesion of the yeast to the tissue of a mammalian host, wherein the molecular weight of the hydrophobic cell wall protein, as determined by SDS-PAGE, is less than about 90 kDa.

67. (previously presented) The hydrophobic cell wall protein of claim 66, wherein the molecular weight is about 36kDa, 38kDa, 40kDa, 41kDa, 54kDa, 55kDa or 59kDa.

68. (previously presented) The protein of claim 67 wherein the host tissue is selected from the group consisting of endothelial cells, epithelial cells or extracellular matrix proteins.

69. (previously presented) The protein of claim 68, wherein the protein is capable of binding to the host tissue under physiological shear conditions present in that tissue.

70. (previously presented) A method of preventing candidiasis in a patient comprising administering to a patient an effective amount of an antibody composition of claim 37.

71. (previously presented) The method of claim 70, wherein the antibody is selected from the group consisting of the monoclonal antibodies 5F8, 5D8, 1C1 and 6C5, and fragments and mixtures thereof.

72. (previously presented) The method of claim 71, wherein the antibody is 1C1 or fragments thereof.

73. (previously presented) The method of claim 70, wherein the monoclonal antibody is humanized.

74. (previously presented) The method of claim 70, wherein the yeast is selected from the group consisting of *C. albicans*, *C. kefir*, *C. lipolytica*, *C. rugosa*, *C. stellatoidea* and *C. tropicalis* and strains thereof.

75. (previously presented) The method of claim 70, wherein the patient is a high risk patient.

76. (previously presented) The method of claim 75, wherein the patient is at high risk due to abdominal surgery, open heart surgery, kidney transplant, bone marrow transplant, in-dwelling catheterization, or the administration of corticosteroids and/or broad-spectrum antibiotics.

77. (previously presented) The method of claim 70, wherein the candidiasis is disseminated candidiasis or mucocutaneous candidiasis.

78. (previously presented) A method of determining whether an antibody that specifically binds to an epitope of a hydrophobic cell wall protein of a yeast from the *Candida* genus will inhibit binding of the yeast to a tissue of a mammalian host comprising:

- a) pretreating the yeast with the antibody,
- b) determining whether the pretreated yeast binds to a tissue of a mammalian host, wherein step (b) is performed under physiological shear conditions.

79. (previously presented) The method of claim 78, wherein the yeast is selected from the group consisting of *C. albicans*, *C. kefyr*, *C. lipolytica*, *C. rugosa*, *C. stellatoidea* and *C. tropicalis* and strains thereof.

80. (previously presented) The method of claim 78, wherein the host tissue is selected from the group consisting of endothelial cells, epithelial cells or extracellular matrix proteins.

81. (new) The hydrophobic cell wall protein of claim 66, wherein said protein is specifically bound by antibody 6C5.

82. (new) The hydrophobic cell wall protein of claim 81, wherein the yeast is selected from the group consisting of *C. albicans*, *C. kefir* and *C. tropicalis*.

83. (new) The hydrophobic cell wall protein of claim 82, wherein the yeast is *C. albicans*.

84. (new) The hydrophobic cell wall protein of claim 83, wherein the protein is about 38 kDa as determined by Western blot analysis with antibody 6C5.